UNSPSC 51172160: Alverine tartrate

This classification denotes an anticholinergic agent C20H27N.C4H6O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 943CL334OB, chemically known as dipropylamine, n-ethyl-3,3'-diphenyl-, tartrate, but more generally known as alverine tartrate, which bears US NIH Compound Identifier 72941455. European Medicines Agency schedules Alverine tartrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB26963.

Most nations, for tariff and trade purposes, schedule alverine tartrate under HS 29214980 and SITC 51454. As of Q4 2014, ALVERINE TARTRATE remains US FDA's Preferred Term for this commodity. SMILES: CCN(CCCC1CCCCC1)CCCC2CCCCC2.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O.

UNSPSC 51172160 Alveoline tartrate (Commodity) represents pharmaceutical active ingredients and finished-form drugs procured by state and local health and criminal justice agencies. Recent state and local solicitations under this code show demand spanning offender drug testing, therapeutic pharmacy initiatives, and multi-state cooperative purchasing of generic pharmaceuticals and over-the-counter products — reflecting both direct-service and bulk-supply procurement models.

State agencies including the Texas Health and Human Services Commission and the Minnesota Department of Administration (administering the Multistate Cooperative Purchasing Alliance) are the primary issuers, joined by county-level criminal justice departments such as Collin County Community Supervision and Corrections. Geographic activity centers on Texas and Minnesota, with multi-state reach through cooperative purchasing vehicles. Representative recent opportunities include Collin County's RFP 2026-327 for offender specimen collection and drug testing services (due July 23, 2026, estimated value $600,000 over two years with three optional one-year renewals) requiring SAMHSA, Texas DPS, or CAP lab certification and approximately 25,031 annual tests via screening and confirmation protocols; the Texas HHS Commission's RFI HHS0017013 (posted March 27, 2026) soliciting vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager relationships; and the Minnesota MMCAP RFP S1070000015802 for generic multi-source pharmaceuticals and OTC products (due March 26, 2026, effective July 1, 2026) distributed through three authorized wholesalers with pricing evaluation weighted 75 percent toward competitiveness and requiring cGMP certification and Drug Supply Chain Security Act compliance.